Compound ID | 159
Class: Nucleoside analogue
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor. MraY inhibitor / translocase I inhibitor (TLI inhibitor); interferes with cell wall synthesis by inhibiting transfer of the peptidoglycan precursor moiety (MurNAc-pentapeptide) to the membrane lipid carrier, undecaprenyl phosphate |
| Target Pathogen: | Active against Clostridium difficile |
| Description: | Semisynthetic derivative of the natural product capuramycin from Streptomyces griseus |
| Institute where first reported: | Sequella, USA |
| Year first mentioned: | 1986 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/71589730 |
| Guide to Pharmacology: | SQ641 |
| Citations: |
|